Randomized Controlled Trial evaluating Ayurvedic therapies- Siro pichu and Padabhyanga with Ksirabala Taila as an Add on to Cognitive Behavioural Therapy-Insomnia (CBT-I) for the management of Insomnia in Perimenopausal Women
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Change in Insomnia Severity Index total score and Pittsburgh Sleep Quality Index score from baseline to end of intervention
研究概览
简要总结
The single centre parallel group randomized controlled trial is designed to evaluate the efficacy of Ayurvedic therapies Siro pichu and Padabhyanga with Ksirabala Taila as adjuncts to Cognitive Behavioural Therapy for Insomnia in the management of chronic insomnia among perimenopausal women aged 45 to 55 years. Insomnia affects nearly half of women during the menopausal transition and while CBT I is the recommended first line non pharmacological treatment it often requires 4 to 6 weeks for noticeable improvement leading to early discontinuation in up to 30 to 40 percent of patients. Ayurvedic therapies targeting Vata imbalance such as Siro pichu and Padabhyanga are traditionally used to induce relaxation and sleep with preclinical evidence suggesting effects on GABAergic modulation and parasympathetic activation. The trial will enroll eligible women with subthreshold to moderate insomnia after screening and informed consent. Participants will be randomized into two groups: the intervention group will receive CBT I along with Siro pichu for 30 minutes nightly for 7 days and Padabhyanga for twice daily for 14 days while the control group will receive CBT I alone. CBT I will be delivered to both groups through eight standardized sessions over four weeks, supplemented by sleep hygiene counselling. The primary outcomes are mean reduction in the Insomnia Severity Index and Pittsburgh Sleep Quality Index scores after four weeks. Secondary outcomes include early improvement in ISI scores at two weeks, sustained changes in ISI and PSQI during a three month follow up occurrence of adverse events and dependency risk assessed using the Severity of Dependency Scale, and adherence assessed by daily diaries. All Ayurvedic medicines will be sourced from a GMP certified manufacturer and administered under standard operating procedures. Safety will be closely monitored and rescue measures will be available if required. This academic trial, conducted at the Department of Prasuti Tantra and Stri Roga Amrita Ayurveda Hospital aims to generate evidence on whether integrating Ayurvedic therapies with CBT I can provide faster symptomatic relief enhance adherence and sustain sleep benefits without pharmacological risks in perimenopausal women with insomnia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 45.00 Year(s) 至 55.00 Year(s)(—)
- 性别
- Female
入选标准
- •Women aged 45 to 55 years Insomnia Severity Index(ISI ) score in between 8-21; identified by symptoms of difficulty initiating or maintaining sleep, or early morning awakening, occurring at least three nights per week, persisting for a minimum duration of three months, and associated with clinically significant distress or impairment in daytime functioning.
- •Able to understand and comply with CBT instructions.
- •Able to provide written informed consent.
排除标准
- •Known cases of Hypertension, Thyroid disorders, and Diabetes Mellitus.
- •Those who require HRT during their menopausal period.
- •PHQ-9 Depression scale Score greater than
- •Under medication for any psychological or psychiatric disorders & substance use in the past 30 days.
- •Any active medical or neurological conditions causing sleep disruption.
- •No access to mobile phones and internet.
- •Use of sleep inducing medications, anti depressants, anti psychotics or sedatives in the past 30 days BMI greater than 35.
结局指标
主要结局
Change in Insomnia Severity Index total score and Pittsburgh Sleep Quality Index score from baseline to end of intervention
时间窗: Primary Outcome will be assessed at baseline and at four weeks of intervention
次要结局
- Early therapeutic response assessed using Insomnia Severity Index total score at Week 2; longitudinal change in Insomnia Severity Index total score during follow up at Weeks 6 8 10 and 12; change in Pittsburgh Sleep Quality Index score during follow up at Weeks 4 8 and 12; occurrence and characterization of clinically relevant events using validated adverse event and adverse drug reaction monitoring checklist; behavioural dependency risk assessed using Severity of Dependency Scale total score; treatment adherence and fidelity assessed using Daily Sleep and Treatment Engagement Diary(Week 2 Weeks 4 6 8 10 and 12 Baseline to Week 12 and daily during intervention)
研究者
Parvathy Unnikrishnan
Amrita School of Ayurveda
